⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397967 | 0.83 | — | — | |
| SCHEMBL14651687 | 0.81 | TRPA1 (0.67) | — | |
| SCHEMBL5473918 | 0.79 | TRPA1 (0.46) | — | |
| SCHEMBL5839114 | 0.79 | TRPA1 (0.46) | — | |
| SCHEMBL17634264 | 0.73 | — | — | |
| SCHEMBL1709048 | 0.73 | — | — | |
| SCHEMBL11604930 | 0.73 | TRPA1 (0.57) | — | |
| SCHEMBL11029344 | 0.73 | TRPA1 (0.57) | — | |
| SCHEMBL759444 | 0.72 | TRPA1 (0.50) | — | |
| SCHEMBL368519 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170819-B1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S R L (IT) | 2011-09-21 | — | — | EP | claimed |
| US-20100168216-A1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S.R.L. (IT) | 2010-07-01 | — | — | US | claimed |
| EP-2170819-A1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | CTG Pharma S.r.l. (IT) | 2010-04-07 | — | — | EP | claimed |
| WO-2009156466-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CTG PHARMA S.R.L. (IT) | 2009-12-30 | — | — | WO | claimed |
| WO-2009109501-A2 | OCULAR PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S.R.L. (IT) | 2009-09-11 | — | — | WO | claimed |
| WO-2009065926-A2 | NEW ANTICANCER COMPOUNDS | SULFIDRIS S.R.L. (IT) | 2009-05-28 | — | — | WO | claimed |
| US-20090017003-A1 | THIOSULFONATE ANTI-INFLAMMATORY AGENTS | SULFIDRIS S.R.L. (IT) | 2009-01-15 | — | — | US | claimed |
| WO-2008146105-A1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S.R.L. (IT) | 2008-12-04 | — | — | WO | claimed |
| WO-2008077453-A1 | 5-FLUOROURACIL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | SULFIDRIS, S.R.L. (IT) | 2008-07-03 | — | — | WO | claimed |
| EP-1939186-A1 | 5-Fluorouracil derivatives and their use for the treatment of cancer | Sulfidris S.r.l. (IT) | 2008-07-02 | — | — | EP | claimed |
| WO-2007101606-A1 | THIOSULFONATE ANTI-INFLAMMATORY AGENTS | SULFIDRIS S.R.L. (IT) | 2007-09-13 | — | — | WO | claimed |
| EP-1832575-A1 | Anti-inflammatory agents | Sulfidris S.r.l. (IT) | 2007-09-12 | — | — | EP | claimed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| US-20060009375-A1 | Site-specific drug delivery | TORONTO RESEARCH CHEMICALS, INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| EP-0966304-B1 | SITE-SPECIFIC DRUG DELIVERY | DIME DAVID S (CA) | 2005-05-25 | — | — | EP | disclosed |
| EP-0966304-A1 | SITE-SPECIFIC DRUG DELIVERY | Dime, David S. (CA) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998036777-A1 | SITE-SPECIFIC DRUG DELIVERY | DIME DAVID S (CA) | 1998-08-27 | — | — | WO | disclosed |